EUVIMEDEUVIMED entdecken
Crossref

CD161-lectin-like transcript 1 axis beyond programmed cell death protein 1 in hepatitis B virus-associated hepatocellular carcinoma

Hai Nguyen Ngoc Dang, Hau Phuc Tran, Hung Minh Vu, Trung Tran Nguyen, Bich Ngoc Hoang Thi, Thanh Van Ho, Adegbesan Abiodun Christopher, Hung Tran Xuan, Thang Viet Luong

World Journal of Gastrointestinal Oncology · 15.11.2026 · 18 (11)

DOI: 10.4251/wjgo.120101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 15.11.2026. Verfasst von Hai Nguyen Ngoc Dang und 8 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B virus (HBV)-associated hepatocellular carcinoma develops in a chronically inflamed, tolerogenic liver microenvironment. In this setting, T-cell dysfunction limits the efficacy of programmed death-1 (PD-1) blockade. Emerging evidence from Liu et al published in the World Journal of Gastrointestinal Oncology suggests that CD161 may represent an additional inhibitory axis within exhausted CD8+ T cells that is not fully captured by the PD-1/ programmed death ligand-1 pathway. In their study, CD161+CD8+ T cells were enriched in tumor tissue, and CD161 expression persisted even as PD-1+ compartments contracted after PD-1 inhibition, suggesting that CD161-mediated restraint may remain active under therapeutic pressure. Mechanistically, sustained engagement of the CD161-lectin-like transcript 1 interaction may impair T-cell effector function and contribute to adaptive immune resistance in the HBV-infected liver. These findings highlight the importance of protein-level assessment of CD161 and parallel evaluation with PD-1 to accurately characterize immune inhibition. Key knowledge gaps include the cellular source of lectin-like transcript 1 within the tumor microenvironment, the influence of ongoing HBV virological activity on CD161+ T-cell subsets, and the identification of clinically meaningful progression endpoints. In this editorial, we place these findings in mechanistic and translational context, highlighting the potential role of the CD161-lectin-like transcript 1 axis as a complementary pathway of immune resistance beyond PD-1 blockade. Collectively, the current evidence supports a cautious, hypothesis-driven translational strategy to evaluate combined modulation of the CD161 and PD-1 axes in carefully selected patients with HBV-associated hepatocellular carcinoma.

Zitieren

APA

Dang, H. N. N., Tran, H. P., Vu, H. M., Nguyen, T. T., Thi, B. N. H., Ho, T. V., Christopher, A. A., Xuan, H. T., & Luong, T. V. (2026). CD161-lectin-like transcript 1 axis beyond programmed cell death protein 1 in hepatitis B virus-associated hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 18(11). https://doi.org/10.4251/wjgo.120101

Vancouver

Dang HNN, Tran HP, Vu HM, Nguyen TT, Thi BNH, Ho TV, et al. CD161-lectin-like transcript 1 axis beyond programmed cell death protein 1 in hepatitis B virus-associated hepatocellular carcinoma. World Journal of Gastrointestinal Oncology. 2026;18(11). doi:10.4251/wjgo.120101

BibTeX
@article{Dang2026,
  author = {Dang, Hai Nguyen Ngoc and Tran, Hau Phuc and Vu, Hung Minh and Nguyen, Trung Tran and Thi, Bich Ngoc Hoang and Ho, Thanh Van and Christopher, Adegbesan Abiodun and Xuan, Hung Tran and Luong, Thang Viet},
  title = {CD161-lectin-like transcript 1 axis beyond programmed cell death protein 1 in hepatitis B virus-associated hepatocellular carcinoma},
  journal = {World Journal of Gastrointestinal Oncology},
  year = {2026},
  volume = {18},
  number = {11},
  doi = {10.4251/wjgo.120101}
}
Kostenlos starten →